Zipalertinib Plus Chemotherapy Moves Toward FDA Review After Six-Month PFS Benefit in EGFR Exon 20 Insertion-Mutated Lung ...
FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer / Antibody drug conjugates, AstraZeneca, ...
A JAMA Network Open study models how chemotherapy-induced biological aging may affect long-term survival and health in breast ...
Opportunity to Join a Seminar on How a Perturbed Microenvironment Regulates Tumour Cell Function and Therapy Response / ...
A 102-patient study evaluates single-session lung biopsy and cryoablation, reporting 87.3% diagnostic yield and 91.2% ...
Can AI Cure Cancer by 2036? / AI and cancer, AI drug discovery, AI in oncology, Anthropic, artificial intelligence, ...
Bristol Myers Squibb Unifies R&D Under Cristian Massacesi in Major Leadership Restructuring / BMS, Bristol Myers Squibb, ...
Is ARPI Intensification in High-Risk Localized Prostate Cancer a Class Effect? / ARPI, cancer, darolutamide, Enzalutamide, ...
The inaugural Africa Cancer Control Implementation Forum (ACIF) will take place on December 7, 2026, in Abuja, Nigeria, ...
Belzutifan Plus Lenvatinib Moves Closer to EU Approval for Advanced Kidney Cancer / belzutifan, cancer, CHMP, clear cell ...
Discussing How Ethical Dilemmas in Public Health Shape Communication with Patients and the Public / cancer, Christos ...
Opportunity to Join the Young Adult Cancer Symposium Hosted by Vanderbilt-Ingram Cancer Center / AYACSM, cancer, Cathy Eng, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results